日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

瑞博西尼联合内分泌治疗激素受体阳性/ERBB2阴性早期乳腺癌:NATALEE随机临床试验的4年结果

Fasching, Peter A; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Xu, Binghe; Loi, Sherene; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Hortobagyi, Gabriel N; Slamon, Dennis J; Fresco, Rodrigo; Zarate, Juan Pablo; Li, Zheng; Waters, Sorcha; Hurvitz, Sara A

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

接受瑞博西尼联合非甾体类芳香化酶抑制剂治疗的 HR+/HER2- 早期乳腺癌患者的健康相关生活质量:NATALEE 试验结果

Fasching, Peter A; Slamon, Dennis; Nowecki, Zbigniew; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Chan, Arlene; Chia, Stephen; Martín, Miguel; Rugo, Hope S; Loi, Sherene; Hurvitz, Sara; Untch, Michael; Afenjar, Karen; Fresco, Rodrigo; Danyliv, Andriy; Ferrusi, Ilia; Li, Zheng; Hortobagyi, Gabriel

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

研究总结:曲妥珠单抗德鲁替康治疗HER2表达实体瘤的疗效(按入组HER2 IHC状态划分):DESTINY-PanTumor02研究的事后分析

Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Jung, Kyung Hae; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

曲妥珠单抗德鲁替康治疗HER2表达实体瘤患者的疗效和安全性:DESTINY-PanTumor02 II期试验的主要结果

Meric-Bernstam, Funda; Makker, Vicky; Oaknin, Ana; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Jung, Kyung Hae; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Ma, Yan; Puvvada, Soham; Shire, Norah; Lee, Jung-Yun

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

曲妥珠单抗德鲁替康治疗HER2表达实体瘤的疗效(按入组时HER2 IHC状态划分):DESTINY-PanTumor02研究的事后分析

Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Jung, Kyung Hae; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda

Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

SUNLIGHT 研究简明语言摘要:三氟尿苷/替吡嘧啶联合贝伐珠单抗治疗难治性转移性结直肠癌

Prager, Gerald W; Taieb, Julien; Fakih, Marwan; Ciardiello, Fortunato; Van Cutsem, Eric; Élez, Elena; Wyrwicz, Lucjan; Stroyakovskiy, Daniil; Liposits, Gabor; Bondarenko, Igor; Modest, Dominik P; Amellal, Nadia; Tabernero, Josep

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma

两种不同起始剂量乐伐替尼联合依维莫司治疗既往接受过治疗的肾细胞癌患者的健康相关生活质量结局

Bergerot, Cristiane; Young Rha, Sun; Pal, Sumanta; Koralewski, Piotr; Stroyakovskiy, Daniil; Alekseev, Boris; Parnis, Francis; Castellano, Daniel; Lyun Lee, Jae; Sunela, Kaisa; Ciuleanu, Tudor; Heng, Daniel; Glen, Hilary; Wang, Jinyi; Bennett, Lee; Pan, Janice; O'Hara, Karen; Puente, Javier

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer

NATALEE 研究的原理和试验设计:一项针对 HR+/HER2- 早期乳腺癌患者的辅助治疗方案(利博西尼联合内分泌治疗与单纯内分泌治疗)的 III 期临床试验

Slamon, Dennis J; Fasching, Peter A; Hurvitz, Sara; Chia, Stephen; Crown, John; Martín, Miguel; Barrios, Carlos H; Bardia, Aditya; Im, Seock-Ah; Yardley, Denise A; Untch, Michael; Huang, Chiun-Sheng; Stroyakovskiy, Daniil; Xu, Binghe; Moroose, Rebecca L; Loi, Sherene; Visco, Frances; Bee-Munteanu, Valerie; Afenjar, Karen; Fresco, Rodrigo; Taran, Tetiana; Chakravartty, Arunava; Zarate, Juan Pablo; Lteif, Agnes; Hortobagyi, Gabriel N

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

评估斯帕塔利珠单抗联合达拉非尼和曲美替尼治疗BRAF V600突变型不可切除或转移性黑色素瘤的随机III期试验

Dummer, Reinhard; Long, Georgina V; Robert, Caroline; Tawbi, Hussein A; Flaherty, Keith T; Ascierto, Paolo A; Nathan, Paul D; Rutkowski, Piotr; Leonov, Oleg; Dutriaux, Caroline; Mandalà, Mario; Lorigan, Paul; Ferrucci, Pier Francesco; Grob, Jean Jacques; Meyer, Nicolas; Gogas, Helen; Stroyakovskiy, Daniil; Arance, Ana; Brase, Jan C; Green, Steven; Haas, Tomas; Masood, Aisha; Gasal, Eduard; Ribas, Antoni; Schadendorf, Dirk

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

IMmotion151 是一项 3 期临床试验,比较了阿特珠单抗联合贝伐珠单抗与舒尼替尼治疗既往未接受治疗的转移性肾细胞癌患者的疗效,本研究的最终总生存期和分子分析结果如下:

Motzer, Robert J; Powles, Thomas; Atkins, Michael B; Escudier, Bernard; McDermott, David F; Alekseev, Boris Y; Lee, Jae-Lyun; Suarez, Cristina; Stroyakovskiy, Daniil; De Giorgi, Ugo; Donskov, Frede; Mellado, Begoña; Banchereau, Romain; Hamidi, Habib; Khan, Omara; Craine, Veronica; Huseni, Mahrukh; Flinn, Nick; Dubey, Sarita; Rini, Brian I